Who are Paclitaxel protein bound's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): nab-paclitaxel，Cisplatin, Standard of Care: Docetaxel, Cabazitaxel (XRP6258), Paclitaxel injection, Paclitaxel (albumin-bound), Docetaxel (DOC).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/paclitaxel-protein-bound.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Paclitaxel protein bound — Competitive Intelligence Brief

Paclitaxel protein bound (Paclitaxel protein bound) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane; microtubule stabilizer. Area: Oncology.

marketed Taxane; microtubule stabilizer β-tubulin (microtubule) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Paclitaxel protein bound (Paclitaxel protein bound) — Barts & The London NHS Trust. Paclitaxel protein-bound stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and halting cell division in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Paclitaxel protein bound TARGET	Paclitaxel protein bound	Barts & The London NHS Trust	marketed	Taxane; microtubule stabilizer	β-tubulin (microtubule)
nab-paclitaxel，Cisplatin	nab-paclitaxel，Cisplatin	Yang Jianjun, PhD	marketed	Chemotherapy combination (taxane + platinum agent)	Microtubules (paclitaxel); DNA (cisplatin)
Standard of Care: Docetaxel	Standard of Care: Docetaxel	H. Lee Moffitt Cancer Center and Research Institute	marketed	Taxane; microtubule stabilizer	β-tubulin
Cabazitaxel (XRP6258)	Cabazitaxel (XRP6258)	Sanofi	marketed	Taxane; microtubule stabilizer	β-tubulin (microtubule)
Paclitaxel injection	Paclitaxel injection	Guangzhou Double Bioproducts Co., Ltd	marketed	Taxane; microtubule stabilizer	β-tubulin
Paclitaxel (albumin-bound)	Paclitaxel (albumin-bound)	Dai, Guanghai	marketed	Taxane; microtubule stabilizer	β-tubulin (microtubule)
Docetaxel (DOC)	Docetaxel (DOC)	Sun Yat-sen University	marketed	Taxane; microtubule stabilizer	β-tubulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane; microtubule stabilizer class)

Sanofi · 2 drugs in this class
Aravive, Inc. · 1 drug in this class
Athenex, Inc. · 1 drug in this class
Barts & The London NHS Trust · 1 drug in this class
BeyondSpring Pharmaceuticals Inc. · 1 drug in this class
Bio-Thera Solutions · 1 drug in this class
Dai, Guanghai · 1 drug in this class
Fujian Medical University · 1 drug in this class
Guangzhou Double Bioproducts Co., Ltd · 1 drug in this class
H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paclitaxel protein bound — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-protein-bound. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab